Core Insights - CVRx, Inc. reported strong financial results for Q4 and full year 2024, with a focus on expanding its Barostim therapy for heart failure patients [3][4][15] Financial Performance - Q4 2024 revenue reached $15.3 million, a 36% increase from Q4 2023 [4] - U.S. heart failure revenue for Q4 2024 was $14.3 million, reflecting a 41% growth year-over-year [5] - Total revenue for 2024 was $51.3 million, up 31% from 2023 [15] - Gross profit for Q4 2024 was $12.8 million, a 33% increase from the previous year, with a gross margin of 83% [8][19] - The company reported a net loss of $10.7 million for Q4 2024, compared to a net loss of $9.2 million in Q4 2023 [13] Operational Highlights - Active implanting centers increased to 223 as of December 31, 2024, a 25% rise from the previous year [10][17] - The number of sales territories in the U.S. grew to 48, up from 38 in 2023 [17] - R&D expenses for Q4 2024 increased by 25% to $2.8 million, driven by clinical study costs [9] - SG&A expenses rose by 19% to $20.2 million, primarily due to increased headcount and compensation [10] Market Outlook - For Q1 2025, the company anticipates total revenue between $14.5 million and $15.0 million [26] - The full-year 2025 revenue is projected to be between $63.0 million and $65.0 million, with a gross margin between 83% and 84% [31]

MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025. The Company will host a conference call to review its results at 4:30pm ...

The market expects CVRx (CVRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the ...

Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35%Full year revenue expected to be $51.1 million to $51.2 million, representing growth of 30%Fiscal 2025 revenue expected to be between $63.0 million and $65.0 million, representing growth of 23% to 27% MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited fourth quarter and full year 2024 revenue r ...

MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com. About CVRx, I ...

MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. About CVRx, In ...

CVRx (NASDAQ: CVRX ) is an impressive medical device company that has a unique product with impressive top-line growth. Furthermore, recent reimbursement news and approval from medical authorities increases sales potential as insurers are willing to cover Barostim. While I am impressed byAmateur value investor seeking bargains in any market, with a specific focus on emerging markets. Admires great investors such as Li Lu and Peter Lynch, and am not afraid to go against the grain. Willing to buy any company ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------------------------------|--------------------------------------------------------------------------------------------- ...

CVRx, Inc. (NASDAQ:CVRX) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Mike Vallie - Investor Relations Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Macauley Kilbane - William Blair Rohin Patel - JPMorgan Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald. Operator Welcome to CVRx Q3 2024 Earnings Call. At this time, all part ...

CVRx (CVRX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.43 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -26.67%. A quarter ago, it was expected that this medical device company would post a loss of $0.51 per share when it actually produced a loss of $0.65, delivering a surprise of -27.45%. Over the last four quarters, the company has ...